AMARIN CORP PLC\UK

Listed Company

AMRNCIK 0000897448NasdaqAcceleratedPharmaceutical PreparationsX0IEFY ends Dec 31

Period

FY 2025

Revenue

$213.65M

Net Income

$-38.80M

Total Assets

$670.80M

Equity

$459.28M

Shares Out

419.59M

Op. Cash Flow

$6.73M

Business

AMARIN CORP PLC is a pharmaceutical company that commercializes and develops therapeutics to improve cardiovascular health and reduce cardiovascular risk. Its principal marketed product is VASCEPA (icosapent ethyl), an EPA-only prescription capsule approved to reduce triglycerides and to lower residual cardiovascular risk in statin-treated high-risk patients. The company operates through commercial, regulatory, clinical development and manufacturing/supply functions and maintains partnerships for local commercialization. It sells and distributes VASCEPA across the U.S., Europe, China, Canada, MENA, Australia/New Zealand, South Korea, Southeast Asia and other international markets via wholesalers and regional partners.

Summary from filing dated 2025-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue, net	214	229	307	369	583
Less: Cost of goods sold	93	111	102	109	121
Less: Cost of goods sold - restructuring inventory	0	37	39	18	—
Gross margin	121	81	166	242	462
Selling, general and administrative	115	152	200	304	408
Research and development	20	21	22	30	29
Restructuring	36	0	11	14	14
Total operating expenses	171	173	233	348	451
Operating loss	−50	−92	−68	−106	11
Interest income	11	13	12	3	1
Interest expense	−7,000	−7,000	−8,000	−15,000	−129,000
Other income, net	3	1	2	−740,000	−302,000
Loss from operations before taxes	−36	−77	−54	−104	11
Provision for income taxes	−3	−5	−5	−2	−4
Net loss	−39	−82	−59	−106	8
Basic (per share)	−0.09	−0.2	−0.15	−0.26	0.02
Diluted (per share)	−0.09	−0.2	−0.15	−0.26	0.02
Basic (shares)	415	411	408	401	396
Diluted (shares)	415	411	408	401	402

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	135	121	199	218	219
Restricted cash	201,000	300,000	525,000	523,000	4
Short-term investments	168	173	121	92	235
Accounts receivable, net	127	122	134	131	164
Inventory	196	166	259	229	235
Prepaid and other current assets	24	13	12	19	22
Total current assets	650	595	725	689	879
Property, plant and equipment, net	12,000	16,000	114,000	874,000	1
Long-term inventory	0	65	78	164	121
Operating lease right-of-use asset	7	8	8	9	8
Other long-term assets	1	1	1	458,000	456,000
Intangible asset, net	13	16	19	22	24
TOTAL ASSETS	671	685	832	886	1,068
Accounts payable	45	40	53	65	115
Accrued expenses and other current liabilities	149	140	204	193	253
Total current liabilities	194	180	259	259	371
Long-term operating lease liability	6	8	9	10	9
Other long-term liabilities	11	12	9	8	8
Total liabilities	211	199	280	291	401
Commitments and contingencies (Note 7)	—	—	—	—	—
Ordinary Shares, GBP 0.50 par, unlimited authorized; 429,847,579 shares issued, 416,214,102 shares outstanding at December 31, 2025; 422,256,900 shares issued, 411,584,851 shares outstanding at December 31, 2024	310	305	303	299	294
Additional paid-in capital	1,924	1,915	1,899	1,885	1,855
Treasury stock; 13,633,477 shares at December 31, 2025; 10,672,049 shares at December 31, 2024	−67	−65	−64	−62	−61
Accumulated deficit	−1,707	−1,669	−1,586	−1,527	−1,421
Total stockholders equity	459	486	552	595	667
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	671	685	832	886	1,068

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−39	−82	−59	−106	8
Depreciation and amortization	4,000	98,000	160,000	551,000	587,000
Accretion of investments	−4	−6	−4	473,000	2
Stock-based compensation	14	18	16	26	37
Amortization of intangible asset	3	3	3	3	2
Accounts receivable, net	−5	11	−3	33	−9
Inventory	35	105	56	−36	−167
Prepaid and other current assets	−12	−934,000	8	3	9
Other long-term assets	158,000	147,000	−278,000	−2,000	−24,000
Interest receivable	728,000	−70,000	248,000	341,000	738,000
Deferred revenue	—	−5	−10	−1	−2
Accounts payable, accrued expenses and other current liabilities	15	−77	−164,000	−103	52
Other long-term liabilities	−1	2	345,000	581,000	1
Net cash provided by (used in) operating activities	7	−31	7	−180	−67
Maturities of securities	209	233	190	258	394
Purchases of securities	−200	−279	−215	−82	−290
Investment in software and website development costs	—	—	−509,000	−599,000	—
Purchases of furniture, fixtures and equipment	—	—	−24,000	—	4,000
Net cash provided by (used in) investing activities	9	−46	−26	175	104
Proceeds from issuance of common stock under employee stock purchase plan	140,000	121,000	330,000	605,000	2
Proceeds from exercise of stock options	0	10,000	2	100,000	3
Taxes related to stock-based awards	−2	−2	−2	−1	−10
Net cash (used in) provided by financing activities	−2	−1	230,000	−379,000	−5
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	14	−78	−18	−5	32
Income taxes, net of refunds	−1	−4	−2	−2	4
Initial recognition of operating lease right-of-use asset	2	1	607,000	2	—
Initial recognition of furniture, fixtures and equipment lease	—	—	624,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro